Figure 3.

HDAC6 inhibitors in neurodegenerative diseases. HDAC6 inhibitors (HDAC6i) have been studied in several diseases (e.g., degenerative, developmental, and following toxins/infection) and have been shown to improve a combination of pathologies including inflammation, cell damage, transport regulation, aggregation, cognition, and disease course. The results shown in this figure reflect studies done with the drugs as indicated. As additional HDAC6i are developed and more studies are performed, additional results could add insight into the overall benefits of this class of drugs. All the drugs indicated are HDAC6i with the exception of Trichostatin A, an inhibitor for class I and II HDAC isoforms.